Navigation Links
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
Date:1/13/2010

BEIJING, Jan. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fifth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan. Under this purchase order, Sinovac is required to deliver an additional 8.57 million doses of PANFLU.1(TM) (15ug/0.5ml) to the Chinese Central Government, of which 2.33 million doses are expected to be delivered before March 15, 2010, and the balance of 6.23 million doses to be stockpiled by the government in Sinovac's warehouse facility.

In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese government for a total 20.05 million doses, and 10.23 million doses of PANFLU.1 have been delivered to date for the Chinese vaccination campaign. In 2009, the Company completed the expansion of its production line used to manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing its annual production capacity by approximately 60%.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "This fifth order from the Chinese Central Government demonstrates Sinovac's continuing ability to complete its national H1N1 vaccine stockpiling tasks in a timely manner. The production capacity expansion has continued to serve its purpose in positioning Sinovac to operate even more efficiently towards our goal of providing citizens of China with affordable, international-quality vaccines."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
2. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
3. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
4. Sinovac Files Shelf Registration Statement
5. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
6. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
7. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
8. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Derma Sciences Obtains Exclusive Worldwide Rights to MEDIHONEY(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017  Allergan plc, (NYSE: AGN ), ... of the International Headache Academy (IHA). Designed to inspire a ... scientists, IHA offers a three-day, intensive overview on research and ... been the sole sponsor since the inception of IHA in ... in Europe in 2014. ...
(Date:1/23/2017)...  Using Astute Medical,s NephroCheck Test ... kidney injury (AKI) after open-heart surgery and providing ... significantly improved outcomes by reducing the occurrence ... percent, according to a study published ... Medicine. Experience the interactive Multimedia ...
(Date:1/23/2017)... YORK , January 23, 2017 ... Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX ), Sophiris Bio ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: ... sector which turned somewhat lower in late trade on Friday, ... Index dropping about 0.3%, while shares of health care companies ...
Breaking Medicine Technology:
(Date:1/24/2017)... KS (PRWEB) , ... January 24, 2017 , ... ... Premensa, a leading natural supplement for relieving premenstrual syndrome, or PMS . ... at some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: ... is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is the creation ... a Christian-based talk show located in Michigan. , “We need to partner with ...
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy and Medically Underserved ... bipartisan original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The ... Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their ...
(Date:1/24/2017)... ... January 23, 2017 , ... The ... Buzzies users who entered metrics into the product’s app. The data replicates ... data showed that within just 30 seconds of using Buzzies, people experienced a ...
(Date:1/23/2017)... ... 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s 26th ... at the Firm, will participate in the 40th Annual "Empire State Building Run Up" ... up 1,576 steps, a vertical distance equal to about a fifth of a mile, ...
Breaking Medicine News(10 mins):